Correlation and association of plasma interleukin-6 and plasma platelet-derived microparticles, markers of activated platelets, in healthy individuals

Thrombosis Research

Volumn 125, Issue 6, 2010, Pages

  Ueba, Tetsuya ^a   Nomura, Shosaku ^a   Inami, Norihito ^b   Nishikawa, Tomofumi ^a   Kajiwara, Motohiro ^a   Iwata, Ryoichi ^a   Yamashita, Kohsuke ^a  

^a Kishiwada City Hospital   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

activated platelet; interleukin 6; platelet derived microparticles; proinflammatory factor

Indexed keywords

C REACTIVE PROTEIN; GLYCOPROTEIN; GLYCOPROTEIN IB ALPHA; GLYCOPROTEIN IX; INTERLEUKIN 6; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; NORMAL HUMAN; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; BLOOD; BLOOD PRESSURE; CROSS-SECTIONAL STUDY; EPIDEMIOLOGY; JAPAN; MEMBRANE MICROPARTICLE; MULTIVARIATE ANALYSIS; SEX DIFFERENCE;

ADULT; BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CELL-DERIVED MICROPARTICLES; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-6; JAPAN; MALE; MULTIVARIATE ANALYSIS; PLATELET ACTIVATION; PLATELET COUNT; SEX FACTORS;

EID: 77952673125     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.03.004     Document Type: Article

References (50)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
2. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
3. Debing E., Peeters E., Demanet C., De Waele M., and Van den Brande P. Markers of inflammation in patients with symptomatic and asymptomatic carotid artery stenosis: A case-control study. Vasc Endovascular Surg 42 (2008) 122-127
4. Rodríguez-Yáñez M., and Castillo J. Role of inflammatory markers in brain ischemia. Curr Opin Neurol 21 (2008) 353-357
5. Welsh P., Lowe G.D., Chalmers J., Campbell D.J., Rumley A., Neal B.C., et al. Associations of proinflammatory cytokines with the risk of recurrent stroke. Stroke 39 (2008) 2226-2230
6. Brevetti G., Piscione F., Silvestro A., Galasso G., Di Donato A., Oliva G., et al. Increased inflammatory status and higher prevalence of three-vessel coronary artery disease in patients with concomitant coronary and peripheral atherosclerosis. Thromb Haemost 89 (2003) 1058-1063
7. Shenhar-Tsarfaty S., Assayag E.B., Bova I., Shopin L., Berliner S., Shapira I., et al. Early signaling of inflammation in acute ischemic stroke: clinical and rheological implications. Thromb Res 122 (2008) 167-173
8. Hoshi T., Kitagawa K., Yamagami H., Furukado S., Hougaku H., and Hori M. Relation between interleukin-6 level and subclinical intracranial large-artery atherosclerosis. Atherosclerosis 197 (2008) 326-332
9. Kerr R., Stirling D., and Ludlam C.A. Interleukin 6 and haemostasis. Br J Haematol 115 (2001) 3-12
10. Licata G., Tuttolomondo A., Raimondo D.D., Corrao S., Sciacca R.D., and Pinto A. Immuno-inflammatory activation in acute cardio-embolic strokes in comparison with other subtypes of ischaemic stroke. Thromb Haemost 101 (2009) 929-937
11. Lindmark E., Diderholm E., Wallentin L., and Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease. Effects of an early invasive or noninvasive strategy. JAMA 286 (2001) 2107-2113
12. Noto D., Cottone S., Baldassare Cefalù A., Vadalà A., Barbagallo C.M., Rizzo M., et al. Interleukin 6 plasma levels predict with high sensitivity and specificity coronary stenosis detected by coronary angiography. Thromb Haemost 98 (2007) 1362-1367
13. Rattazzi M., Puato M., Faggin E., Bertipaglia B., Zambon A., and Pauletto P. C-reactive protein and interleukin-6 in vascular disease: Culprits or passive bystanders?. J Hypertens 21 (2003) 1787-1803
14. Ridker P.M., Rifai N., Stampfer M.J., and Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 (2000) 1767-1772
15. Ridker P.M. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: From concept to clinical practice to clinical benefit. Am Heart J 148 (2004) 19-26
16. Shbaklo H., Holcroft C.A., and Kahn S.R. Levels of inflammatory markers and the development of the post-thrombotic syndrome. Thromb Haemost 101 (2009) 505-512
17. Heinrich P.C., Castell J.V., and Andus T. Interleukin-6 and the acute phase response. Biochem J 265 (1990) 621-636
18. Papanicolaou D.A., Wilder R.L., Manolagas S.C., and Chrousos G.P. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 128 (1998) 127-137
19. Fried S.K., Bunkin D.A., and Greenberg A.S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83 (1998) 847-850
20. Kern P.A., Ranganathan S., Li C., Wood L., and Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280 (2001) 745-751
21. Fernandez-Real J.M., Vayreda M., Richart C., Gutierrez C., Broch M., Vendrell J., et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 86 (2001) 1154-1159
22. Yudkin J.S., Stehouwer C.D., Emeis J.J., and Coppack S.W. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunctionn - a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 19 (1999) 972-978
23. Zuliani G., Volpato S., Blè A., Bandinelli S., Corsi A.M., Lauretani F., et al. High interleukin-6 plasma levels are associated with low HDL-C levels in community-dwelling older adults: The In Chianti study. Atherosclerosis 192 (2007) 384-390
24. Koren-Morag N., Goldbourt U., and Tanne D. Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: A prospective cohort study in patients with atherosclerotic cardiovascular disease. Stroke 36 (2005) 1366-1371
25. Kurl S., Laukkanen J.A., Niskanen L., Laaksonen D., Sivenius J., Nyyssönen K., et al. Metabolic syndrome and the risk of stroke in middle-aged men. Stroke 37 (2006) 806-811
26. Wiberg B., Sundström J., Arnlöv J., Terént A., Vessby B., Zethelius B., et al. Metabolic risk factors for stroke and transient ischemic attacks in middle-aged men: A community-based study with long-term follow-up. Stroke 37 (2006) 2898-2903
27. Devaraj S., Rosenson R.S., and Jialal I. Metabolic syndrome: An appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Amer 33 (2004) 431-453
28. Diamant M., and Tushuizen M.E. The metabolic syndrome and endothelial dysfunction: Common highway to type 2 diabetes and CVD. Curr Diab Rep 6 (2006) 279-286
29. Galassi A., Reynolds K., and He J. Metabolic syndrome and risk of cardiovascular disease: A meta-analysis. Am J Med 119 (2006) 812-819
30. Ueba T., Haze T., Sugiyama M., Higuchi M., Asayama H., Karitani Y., et al. Level, distribution and correlates of platelet-derived microparticles in healthy individuals with special reference to the metabolic syndrome. Thromb Haemost 100 (2008) 280-285
31. Freyssinet J.M. Cellular microparticles: What are they bad or good for ?. J Thromb Haemost 1 (2003) 1655-1662
32. Lee Y.J., Jy W., Horstman L.L., Janania J., Reyes Y., Kelley R.E., et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb Res 72 (1993) 295-304
33. Nomura S., Tandon N.N., Nakamura T., Cone J., Fukuhara S., and Kambayashi J. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis 158 (2001) 277-287
34. Nomura S. Function and clinical significance of platelet-derived microparticles. Int J Hematol 74 (2001) 397-404
35. Mause S.F., von Hundelshausen P., Zernecke A., Koenen R.R., and Weber C. Platelet microparticles: A transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol 25 (2005) 1512-1518
36. Tan K., and Lip G.Y. Platelet microparticles and platelet adhesion: Therapeutic implications for the prevention and treatment of stroke. Curr Treat Options Cardiovasc Med 8 (2006) 251-258
37. Vidal C., Spaulding C., Picard F., Schaison F., Melle J., Weber S., et al. Flow cytometry detection of platelet procoagulant activity and microparticles in patients with unstable angina treated by percutaneous coronary angioplasty and stent implantation. Thromb Haemost 86 (2001) 784-790
38. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
39. Satoh A., Adachi H., Tsuruta M., Hirai Y., Hiratsuka A., Enomoto M., et al. High plasma level of remnant-like particle cholesterol in the metabolic syndrome. Diabetes Care 28 (2005) 2514-2518
40. Kanatani K., and Nomura S. A method for measurement of platelet-derived microparticles. Jpn J Thromb Hemostasis 18 (2007) 653-659
41. Jenny N.S., Tracy R.P., Ogg M.S., Luong le A., Kuller L.H., Arnold A.M., et al. In the elderly, interleukin-6 plasma levels and the -174G > C polymorphism are associated with the development of cardiovascular disease. Arterioscler Thromb Vasc Biol 22 (2002) 2066-2071
42. Lowe G.D., Rumley A., McMahon A.D., Ford I., O'Reilly D.S., Packard C.J., et al. Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol 24 (2004) 1529-1534
43. Tuomisto K., Jousilahti P., Sundvall J., Pajunen P., and Salomaa V. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb Haemost 95 (2006) 511-518
44. Wannamethee S.G., Whincup P.H., Rumley A., and Lowe G.D. Inter-relationships of interleukin-6, cardiovascular risk factors and the metabolic syndrome among older men. J Thromb Haemost 5 (2007) 1637-1643
45. Peng J., Friese P., George J.N., Dale G.L., and Burstein S.A. Alteration of platelet function in dogs mediated by interleukin-6. Blood 83 (1994) 398-403
46. Ishibashi T., Kimura H., Uchida T., Kariyone S., Friese P., and Burstein S.A. Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc Natl Acad Sci USA 86 (1989) 5953-5957
47. Caine G.J., Lip G.Y., Stonelake P.S., Ryan P., and Blann A.D. Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb Haemost 92 (2004) 185-190
48. Chirinos J.A., Zambrano J.P., Virani S.S., Jimenez J.J., Jy W., Ahn E., et al. Correlation between apoptotic endothelial microparticles and serum interleukin-6 and C-reactive protein in healthy men. Am J Cardiol 95 (2005) 1258-1260
49. Skjelland M., Michelsen A., Brosstad F., Svennevig J.L., Brucher R., and Russell D. Solid cerebral microemboli and cerebrovascular symptoms in patients with prosthetic heart valves. Stroke 39 (2008) 1159-1164
50. Wagner D.D., and Burger P. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 23 (2003) 2131-2137